Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
8,165,808
-
Total 13F shares
-
64,725,654
-
Share change
-
-22,738,808
-
Total reported value
-
$33,190,425
-
Put/Call ratio
-
2.1%
-
Price per share
-
$0.51
-
Number of holders
-
89
-
Value change
-
-$41,739,808
-
Number of buys
-
44
-
Number of sells
-
67
Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q4 2023
As of 31 Dec 2023,
Atara Biotherapeutics, Inc. - Common Stock (ATRA) was held by
89 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,725,654 shares.
The largest 10 holders included
EcoR1 Capital, LLC, Redmile Group, LLC, BlackRock Inc., VANGUARD GROUP INC, UBS Group AG, AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, STATE STREET CORP, JPMORGAN CHASE & CO, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
89
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.